Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
Authors:
Open Access
- 9 December 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e001591
Abstract
T cells that recognize self-antigens and mutated neoantigens are thought to mediate antitumor activity of immune checkpoint blockade (ICB) in melanoma. Few studies have analyzed self and neoantigen-specific T cell responses in patients responding to ICB. Here, we report a patient with metastatic melanoma who had a durable clinical response after treatment with the programmed cell death protein 1 inhibitor, nivolumab, combined with the first-in-class CD122-preferential interleukin-2 pathway agonist, bempegaldesleukin (BEMPEG, NKTR-214). We used a combination of antigen-specific T cell expansion and measurement of interferon-γ secretion to identify multiple CD4+ and CD8+ T cell clones specific for neoantigens, lineage-specific antigens and cancer testis antigens in blood and tumor from this patient prior to and after therapy. Polyclonal CD4+ and CD8+ T cells specific to multiple neoantigens but not self-antigens were highly enriched in pretreatment tumor compared with peripheral blood. Neoantigen, but not self-antigen-specific T cell clones expanded in frequency in the blood during successful treatment. There was evidence of dramatic immune infiltration into the tumor on treatment, and a modest increase in the relative frequency of intratumoral neoantigen-specific T cells. These observations suggest that diverse CD8+ and CD4+ T cell clones specific for neoantigens present in tumor before treatment had a greater role in immune tumor rejection as compared with self-antigen-specific T cells in this patient. Trial registration number: NCT02983045.Keywords
Funding Information
- Bezos Family
- Lembersky Family
- National Cancer Institute (K12 CA076930-16A1)
This publication has 22 references indexed in Scilit:
- Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancersNature Medicine, 2018
- The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor ImmunityCancer Immunology Research, 2018
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancerNature, 2017
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung CancerCancer Discovery, 2017
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 2016
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patientsNature Medicine, 2016
- Neoantigens in cancer immunotherapyScience, 2015
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNature, 2014
- The response of autologous T cells to a human melanoma is dominated by mutated neoantigensProceedings of the National Academy of Sciences, 2005
- The Makings of a Tumor Rejection AntigenImmunity, 1999